2015全球疫苗抗体产业(中国)峰会

由于全球人口的老龄化，肥胖人口比例的上升，和全球范围内呼吁通过疫苗来预防疾病减少发病率，全球生物制药产业发展迅猛，特别是为癌症和风湿性关节炎等疾病治疗的抗体药物和下一代创新型疫苗的需求增长神秘嘉宾明显。如今生物制药厂商需要以更快速度为当地市场的医疗需求做出反应并把高质量药物尽快推向市场。 

有鉴于此，由美中药协(SAPA-GP)和国际血清行业协会（ISIA）共同举办的“2015全球疫苗抗体产业(中国)峰会”将于2015年5月7日至8日在上海锦江汤臣洲际大酒店举行。在此，我们诚挚的邀请您参与此次盛会。

 （2015全球疫苗抗体产业(中国)峰会）

峰会将以“加强亚洲生物制药产业的研发合作、推动灵活及创新的生产模式、加快产业化发展的速度”为主题，通过峰会的举办希望为医药公司与生物技术公司的研发合作、生产工艺及设备提供商与生物制药公司生产新项目的对接，生物技术公司为拓宽融资渠道与风险投资商的对话，搭建一个高规格的社交及商业洽谈的平台。 

（2015全球疫苗抗体产业(中国)峰会）

本次会议旨在通过对活跃在亚洲市场的具有行业领导地位的生物制药公司在疫苗、抗体、生物仿制药等药物开发的研发管道、在中国开展的技术转移和新厂房建设战略、及合作模式等方面的进行深入解读，从而为与会代表带来生物药研发、生产、厂房运营、质量与风险管理、合规等方面的最佳实践和案例分析。峰会将聚集来自药物监管及审评机构、国内外知名生物制药公司、生物技术公司、CMO公司、CRO公司、医药咨询公司、律所、生产设备提供商等业内200位高层领导，创造面对面的交流平台。 

Due to declining research and development productivity, stringent regulatory activities and generic competition for off patent product, the traditional pharma industry is stagnant. On the contrary, biopharma industry (which mainly refers to antibody and vaccine) has developed as highly profitable because of advancements in genomics and manufacturing technologies as well as increasing demand from emerging economies. It is estimated that the global sales revenue of biotech drugs will account for more than one-third of all kinds of drug sales by 2020. China's biopharma market is expected to reach 100 billion US dollars by 2015.

Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2013, the market size of monoclonal antibody agents grew at a CAGR of 13%, far higher than the overall growth rate of biopharmaceuticals in the same period. In 2013-2017, the mab market size will hit USD141 billion in 2017 in which Chinese monoclonal antibody market is predicted grow at 35%, sharing 21.5% of the global monoclonal antibody market in 2017 (9.5% in 2012). Meanwhile in the last 2 years, biobetters and ADCs are gaining increasing global attention due to its superior performance. Many of the Asian mAb biosimilar developers have also turned their interests to biobetter development.

Looking into global vaccine market, the market, which stood at US$ 30.5 Billion in 2013, is expected to grow at a CAGR of around 12% during 2013-2020. Asia-Pacific (APAC) region is an attractive market for seasonal influenza vaccine manufacturers. Traditional egg based manufacturing of seasonal influenza vaccines is being replaced with cell culture vaccines. Cell culture based production of vaccines is expected to reduce the problems associated with the production and use of seasonal influenza vaccines which will further increase the vaccination coverage in the APAC region.

In recognition of fast growing biopharma market in Asia and increasing volume of technology transfer and licensing deals happening in Asia to drive the biopharma innovation, Global Vaccine and Antibody China Summit 2015 (GVAC 2015) will convene in Shanghai in May. It is the premier international summit of its kind in China to cover the whole value chain of biologics industry from Biosimilars and Biobetters, BioProcessing, BioAnalytical to BioPartnerships and Therapeutic Vaccines. GVAC 2015 will draw 200+ top antibody and vaccine leaders from global together with experts from biotech, clinical trials, gene engineering, antibody engineering, cell cultures, and related products and technologies to explore innovation and partnership opportunities in biopharma industry in Asia. Built upon the long-standing and successful organization of Vaccine Forum in China over the years, GVAC delivers a unique new networking concept, combining unparallel learning and partnering opportunities for the global industry players, manufacturing and R&D executive, plus key external stakeholders including NGOs and public and private sector investors to brainstorm how to bring the vibrant China’s and Asian biopharma market to the next level. We look forward to seeing you in May, 2015 in Shanghai, China. 

We look forward to seeing you in Shanghai!